PRODUCT

°í°´¸¸Á·À» À§ÇØ Áö¼ÓÀûÀ¸·Î °í¹ÎÇϰí Çõ½ÅÇÏ¿© ÃÖ°íÀÇ Ç°ÁúÀ» Á¦°øÇÕ´Ï´Ù.

R&D reagents

Product > R&D reagents
Brimonidine tartrate, 98%
CAS No W0014-10mg
Á¦Ç°¹øÈ£ AK Sci.(USA)
Á¦Á¶»ç ¼öÀÔ»ê
Àç°í 1 EA
±Ý¾× 88,000¿ø
Æ÷Àå´ÜÀ§
Æ÷Àå´ÜÀ§





¡Ø È­Çиí : Brimonidine tartrate, 98%

 

¡Ø µî±Þ : APIs and Bioactives > Adrenergic Agonists

 

¡Ø ÆÇ¸Å Æ÷Àå´ÜÀ§ : 10mg , 25mg , 100mg

 

¡Ø È­ÇÐ½Ä : C11H10BrN5.C4H6O6

 

¡Ø CAS # : [70359-46-5]

 

 

 

IDENTITY
CAS Registry #:

 

[70359-46-5]

MDL Number: MFCD07773072
MF: C11H10BrN5.C4H6O6
MW: 442.224
SPECIFICATIONS & PROPERTIES
Purity: 98%
Physical Form: Light yellow powder
Melting Point: 213-218¡ÆC
Long-Term Storage:

 

Store long-term at -20¡ÆC

Shipping: Not Regulated for Shipping

REVIEW

Brimonidine is an alpha adrenergic receptor agonist (primarily alpha-2). It has a peak ocular hypotensive effect occurring at two hours post-dosing. Fluorophotometric studies in animals and humans suggest that Brimonidine has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow.

REFERENCES
[1] Toris, C.; Camras, C.; Yablonski, M. (1999). Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. American journal of ophthalmology 128 (1): 8-14. PMID 10482088.

Risk Description(s)
R36/37/38: Irritating to eyes, respiratory system and skin

Safety Description(s)
S24/25: Avoid contact with skin and eyes.